Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison

Expert Review of Hematology · Published 2026-06-19 · DOI 10.1080/17474086.2026.2686813

Free full text

Authors (11)

Naveen Pemmaraju, Alessandro Lucchesi, Stephen T. Oh, Koo Wilson, Zalmai Hakimi, Sarah A. Buckley, Purvi Suthar, Mikolaj Parkitny, Piotr Wojciechowski, Klaudia Kolonko, John O. Mascarenhas

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Pemmaraju, N., Lucchesi, A., Oh, S., et al. (2026). Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison. Expert Review of Hematology. https://doi.org/10.1080/17474086.2026.2686813

Related articles

• Polycythemia vera and metabolic syndrome: is the relationship between the two diseases more than we think? · Expert Review of Hematology · 2026 · Same journal
• Challenges faced by women and girls with hemophilia/Carriers: an expert call for closing the diagnosis gap · Expert Review of Hematology · 2026 · Same journal
• Social challenges and support needs of patients with hemophilia in Pakistan: a qualitative exploratory study · Expert Review of Hematology · 2026 · Same journal
• Autoimmune cytopenias in chronic lymphocytic leukemia in the era of novel drugs · Expert Review of Hematology · 2026 · Same journal
• A Review of Disparities in Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma · Expert Review of Hematology · 2026 · Same journal
• An interview with Dr Joshua Richter on his experience as an investigator for linvoseltamab-gcpt - by Reegan Burnell-Clarke (Commissioning Editor) · Expert Review of Hematology · 2026 · Same journal
• Reconsidering time from diagnosis to treatment in acute myeloid leukemia: from therapeutic urgency to biologically informed timing · Expert Review of Hematology · 2026 · Same journal
• Apparent plateaus during iron chelation in transfusion-dependent β-thalassemia: interpretation and clinical implications · Expert Review of Hematology · 2026 · Same journal
• Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia · Expert Review of Hematology · 2026 · Same journal
• Improving multidisciplinary tailored care models for bleeding disorders · Expert Review of Hematology · 2026 · Same journal